Compare JPMorgan Ultra Short Income ETF (JPST) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Organon & Co. Common Stock — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.31 (market cap $42.48B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 11.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Organon & Co. Common Stock for 0 Days on average.
| JPST | OGN | |
|---|---|---|
Market Cap | $42.48B | $3.62B |
Volume | 7,443,811 | 2,892,999 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $13.81 |
52-Week Low | $50.22 | $5.70 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.31 with minimal daily movement, reflecting its ultra-short bond strategy focused on capital preservation. The technical picture shows bearish momentum with RSI indicators mixed, while fundamental data remains limited for this income-focused ETF. Recent news highlights institutional positioning changes and ongoing investor interest in ultrashort bond strategies amid rate uncertainty.
JPST offers investors exposure to high-quality, short-duration bonds with regular dividend distributions. The fund faces competition from similar ultrashort ETFs and sensitivity to Federal Reserve policy changes. Current market conditions favor cash-alternative strategies, though expense ratios and active management performance remain key considerations for investors seeking yield with minimal risk.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
